TNBC - Triple-Negative Breast Cancer Clinical Trials

85 clinical trials for TNBC - Triple-Negative Breast Cancer across international registries, including 38 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• First in Human Study of TUB-030 in Patients With Advanced Solid Tumors — RECRUITING · PHASE1
• Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer — RECRUITING · PHASE2
• Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05) — RECRUITING
• Study of Radiotherapy Combined With Platinum, Adebrelimab and Bevazumab in the Treatment of TNBC-BM. — RECRUITING · PHASE2
• BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia — RECRUITING · PHASE1
• Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies — RECRUITING
• Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC) — RECRUITING · PHASE2
• QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride and Nab-Paclitaxel as First-Line Treatment for Advanced Triple-Negative Breast Cancer — RECRUITING · PHASE2
• Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer — RECRUITING · PHASE1
• I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer — RECRUITING · PHASE2
• Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer — RECRUITING
• Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation — RECRUITING · PHASE2
• Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK — RECRUITING · PHASE2
• 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors — RECRUITING · PHASE1
• Neoadjuvant Toripalimab Plus SBRT for Chemo-Resistant Triple-Negative Breast Cancer — RECRUITING · PHASE2
• 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors — RECRUITING · PHASE1
• NearWave Optical Molecular Monitoring — RECRUITING · NA
• A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer — RECRUITING · PHASE2
• Immunotherapy-related CRP Kinetics in Early and Metastatic Triple-negative Breast Cancer — RECRUITING
• SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC — RECRUITING · PHASE3
• Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07) — RECRUITING · PHASE2
• Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer — RECRUITING · PHASE1
• Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02) — RECRUITING · PHASE2
• MRI-Guided Neoadjuvant Treatment De-Escalation in Stage II-III TNBC — RECRUITING · PHASE2
• A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBC — RECRUITING · PHASE1
• Study of AVZO-021 in Patients With Advanced Solid Tumors — RECRUITING · PHASE1
• PSMA-PET/CT to Assess the Expression of Specific Membrane Antigen (PSMA) in Patients With Progressive Triple-negative Breast Cancer. — RECRUITING · PHASE2
• A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer — RECRUITING · PHASE3
• Role of the Immune Environment in Response to Therapy in Breast Cancer — RECRUITING
• Trop-2 Targeted PET Probes in Advanced TNBC — RECRUITING · NA
• A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer — RECRUITING · PHASE2
• QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC — RECRUITING · PHASE2
• CtDNA Based MRD Testing for NAC Monitoring in TNBC — RECRUITING
• Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study — RECRUITING · PHASE2
• LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer — RECRUITING · PHASE2
• A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01) — RECRUITING · PHASE3
• The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical Study — RECRUITING · PHASE2
• Estrogen Receptor (ER) PET/CT Imaging in Breast Cancer — RECRUITING
• Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies — NOT_YET_RECRUITING · PHASE1
• Phase II Trial of Pembrolizumab/Chemotherapy With Live Biotherapeutic Product MO-03 in Patients With Early Stage Triple Negative Breast Cancer — NOT_YET_RECRUITING · PHASE2
• Phase 3 Trial of SRG-514 Administered Intraoperatively to Patients Undergoing Breast-Conserving Surgery — NOT_YET_RECRUITING · PHASE3
• First-line Nab-paclitaxel Plus Cisplatin Plus Camrelizumab in mTNBC Patients — COMPLETED · PHASE2
• Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer — COMPLETED · PHASE1
• Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC — NOT_YET_RECRUITING · PHASE1
• A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer — TERMINATED · PHASE1
• A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• Study of LP-184 in Patients With Advanced Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• An Open-Label, Multicenter, Non-Randomized Expanded Access Protocol (EAP) Designed to Provide Leronlimab to Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer (mTNBC) — OTHER
• ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation — NOT_YET_RECRUITING · PHASE2
• Comparison of Chemotherapy and Immunotherapy in Neoadjuvant Therapy for TNBC — NOT_YET_RECRUITING

Refine this search